Market closedADR
Genmab/$GMAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Genmab
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Ticker
$GMAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Copenhagen, Denmark
Employees
2,635
Website
Genmab Metrics
BasicAdvanced
$13B
2.07
$10.06
0.86
-
Price and volume
Market cap
$13B
Beta
0.86
52-week high
$31.88
52-week low
$19.85
Average daily volume
1.1M
Financial strength
Current ratio
5.169
Quick ratio
5.153
Long term debt to equity
2.807
Total debt to equity
3.092
Interest coverage (TTM)
149.16%
Management effectiveness
Return on assets (TTM)
10.95%
Return on equity (TTM)
14.92%
Valuation
Price to earnings (TTM)
2.068
Price to revenue (TTM)
0.486
Price to book
3
Price to tangible book (TTM)
5.32
Price to free cash flow (TTM)
1.471
Growth
Revenue change (TTM)
17.75%
Earnings per share change (TTM)
14.35%
3-year revenue growth (CAGR)
35.90%
3-year earnings per share growth (CAGR)
18.40%
What the Analysts think about Genmab
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Genmab Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Genmab Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Genmab News
AllArticlesVideos
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·3 weeks ago
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
GlobeNewsWire·1 month ago
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $13B as of January 22, 2025.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 2.07 as of January 22, 2025.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of January 22, 2025.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.